Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of STAT3 in diffuse large B-cell lymphoma

ABSTRACT: Genome-wide analysis of STAT3 in diffuse large B-cell lymphoma

PROVIDER: PRJNA418173 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6286180.fastq.gz	Fastqsanger.gz
	SRR6286181.fastq.gz	Fastqsanger.gz
	SRR6286182.fastq.gz	Fastqsanger.gz
	SRR6286173.fastq.gz	Fastqsanger.gz
	SRR6286174.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Genome-wide analysis of pSTAT3 (Tyr705) in diffuse large B-cell lymphoma

Project description:Diffuse large B cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma, includes two main molecular subtypes: activated B cell-like (ABC) DLBCL and germinal center B cell-like (GCB) DLBCL. ABC DLBCL is more aggressive, with the activated JAK1-STAT3 pathway that promotes cell survival. In order to study the underlying pathogenic mechanism, we performed a ChIP-seq experiment by phospho-STAT3(Tyr705) antibody in ABC DLBCL cell lines, and identified 3,456 STAT3 target genes genome-wide. In parallel, ChIP-seq experiment was performed with STAT3 antibody in α-IgM stimulated naïve B cells for verification of these targets of STAT3 protein. TMD8 was treated by eithor DMSO or AZD1480 (JAK inhibitor) for 4hrs, ChIP-seq experiments were performed by pSTAT3(Tyr705) antibody (#9145S, Cell signaling). Naïve B cells were collected from peripheral blood mononuclear cells by Naive B Cell Isolation kit (miltenyi biotec; 130-091-150), and treated by 10ug/ml α-IgM (southernbiotech; #2020-01) for 24hrs. ChIP-seq experiments were performed by STAT3 antibody (SC-482X, Santa Cruz).

2019-05-01 | GSE123398 | GEO

Whole genome mapping of STAT3 binding sites in the two major subtypes of diffuse large B cell lymphoma

2013-12-16 | GSE50723 | GEO

Whole genome mapping of STAT3 binding sites in the two major subtypes of diffuse large B cell lymphoma

Project description:The goal of this study is to identify the effect of the transcription factor STAT3 in the two major subtypes of diffuse large B cell lymphoma (DLBCL). STAT3 is a signal transducer that, when dysregulated, becomes a powerful oncogene found in many human cancers, including DLBCL. DLBCL is the most common form of non-Hodgkin’s lymphoma and has two major subtypes: germinal center B-cell-like (GCB) and activated B-cell-like (ABC). When compared to the GCB form, ABC lymphomas respond much more poorly to current therapies and often exhibit overexpression or overactivation of STAT3. To investigate how STAT3 might contribute to this aggressive phenotype, we have used ChIP-Seq to identify STAT3 binding sites in 8 DLBCL cell lines (4 GCB subtype, 4 ABC) that are derived from patient tumors. 10,337 distinct STAT3 binding regions are occupied in at least two of the eight cell lines. One third (n = 3524) are differentially bound by STAT3 between the two subtypes (FDR < 0.05). More BRs are strongly bound in ABC than in GCB: 44% of differentially bound BRs (n = 1550) show more STAT3 binding in GCB, while 56% (n = 1974) are more strongly bound in ABC. Identification and comparison of STAT3 transcription factor binding sites in 8 cell lines that represent the 2 subtypes of DLBCL. 4 cell lines are subtyped as ABC and 4 are subtyped as GCB. 2-9 replicates and 1 input control are present for each cell line. (Cell line OCI-Ly19 was not included in the final analysis because RNA-Seq showed that its gene expression clustered in between the subtypes, probably due to its EBV+ status. However, its peak calls were used in intermediate steps of the analysis pipeline. Its sequencing runs have been included for completeness.)

2013-12-16 | E-GEOD-50723 | biostudies-arrayexpress

EGR1 addiction in diffuse large B cell lymphoma

Project description:Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, including two main molecular subtypes termed activated B cell-like (ABC) and germinal center B cell-like (GCB). ABC DLBCL is less curable and identification of new molecular targets is needed for the development of effective therapeutic agents. Here, we focused on EGR1, a transcription factor that is regulated by the B cell receptor and JAK1/STAT3 signaling pathway in ABC DLBCL. ChIP-Seq and RNA-Seq analyses revealed that gene regulation by EGR1 in ABC DLBCL accentuates multiple oncogenic pathways, including MYC and E2F, while dampening the lethal type I IFN pathway.

2021-08-06 | GSE123291 | GEO

Genome-wide binding of STAT3 or CEBP beta in anaplastic large cell lymphoma

Project description:Examination of STAT3 or CEBP beta binding by ChIP-seq in Crizotinib treated Anaplastic large cell lymphoma.

2018-11-08 | GSE117164 | GEO

Genome-wide analysis of STAT3 in diffuse large B-cell lymphoma

Project description:By genome-wide ChIP-seq analysis in ABC DLBCL cell lines, we identified 2,251 STAT3 direct target genes, which involve B cell activation, survival, proliferation, differentiation and migration. Whole transcriptome profiling revealed that STAT3 acts as both a transcriptional activator and suppressor.

2018-01-01 | GSE106844 | GEO

Genetic variants associated with development of colorectal cancer, type 1 diabetes, Hodgkin lymphoma and Diffuse large B-cell lymphoma

Project description:In our genome-wide association study, we searched for an association of genetic variants with colorectal cancer, type 1 diabetes, Hodgkin lymphoma and Diffuse large B-cell lymphoma among Polish population.

2021-07-02 | GSE156411 | GEO

Genome-wide analysis of pSTAT3 (Tyr705) in diffuse large B-cell lymphoma

Project description:Genome-wide analysis of pSTAT3 (Tyr705) in diffuse large B-cell lymphoma

| PRJNA508625 | ENA

Gene and microRNA expression data of diffuse large B cell lymphoma from human diagnostic frozen samples

Project description:This SuperSeries is composed of the following subset Series: GSE21846: Transcriptional profiling of 29 cases of diffuse large B cell lymphoma GSE21847: miRNA profiling of 29 cases of diffuse large B cell lymphoma GSE21848: miRNA profiling of 36 cases of diffuse large B cell lymphoma Refer to individual Series

2011-08-01 | E-GEOD-21849 | biostudies-arrayexpress

EGR1 addiction in diffuse large B cell lymphoma

Project description:EGR1 addiction in diffuse large B cell lymphoma

| PRJNA508194 | ENA